Clinical trials
Relapsed or Refractory Acute Myeloid Leukemia (AML) clinical trials
Below are recruiting relapsed or refractory acute myeloid leukemia (aml) clinical trials, each written for real people, not researchers. We’re tracking 1,349 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03911128Recruiting
Treatment protocol for newly diagnosed childhood and young adult ALL
This trial tests a standard treatment plan (a protocol) for people aged 0 to under 46 with newly diagnosed ALL, a cancer of the blood and bone marrow. It may help by making sure patients receive the right therapy based on their specific ALL subtype.
AalborgAges birth–45 years - NCT03226704Enrolling by invitation
Leukapheresis to prepare CAR cell therapy
This trial collects white blood cells through a procedure called leukapheresis to help make CAR or other adoptive cell therapies. It’s for people with certain cancers who are not in remission (or are at high risk of relapse) and can meet health and lab requirements.
Bethesda, MarylandAges 3–65 - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT02443831RecruitingPhase 1
CAR T-cell immunotherapy for high-risk childhood leukemia
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
LondonAges Up to 24 years - NCT07463807RecruitingPhase 1/Phase 2
Comparing two drug combinations for multiple myeloma that returned quickly
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
Duarte, CaliforniaAges 18 years+ - NCT07200089RecruitingPhase 1
IL-7 treatment after CAR-T therapy for multiple myeloma
This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.
St Louis, MissouriAges 18 years+ - NCT02259556RecruitingPhase 1/Phase 2
CAR T treatment for CD30-positive lymphomas after standard therapies
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
Beijing, Beijing MunicipalityAges 16–80 - NCT03494296Recruiting
Low-dose decitabine plus COP for relapsed lymphoma
This trial studies whether a low-dose chemotherapy medicine (decitabine) combined with a COP chemotherapy regimen can help adults whose diffuse large B-cell lymphoma (DLBCL) has come back or did not respond to treatment. It may be an option if you have measurable disease and can meet key safety and health requirements.
Harbin, HeilongjiangAges 18 years+ - NCT03196414RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed myeloma with multiple targets
This trial tests an immune therapy made from T cells to attack multiple markers on multiple myeloma cells (including CD138 and BCMA). It may help people whose myeloma has come back or resisted treatment, when there are no curative options left.
Suzhou, JiangsuAges 18–75 - NCT03356054RecruitingPhase 1/Phase 2
Test drug for CD30-positive lymphoma after first treatment fails
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
RotterdamAges 18 years+ - NCT05166070RecruitingEarly Phase 1
RD133 for mesothelin-positive tumors after prior treatments
This early-phase study tests RD133, an experimental treatment, in adults whose solid tumors are mesothelin-positive and have come back or not responded to prior standard therapies. It aims to see how well RD133 can control these cancers and what side effects it causes.
Nanjing, JiangsuAges 18 years+ - NCT05272371RecruitingPhase 1
Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Krakow, MalopolskaAges 1–18 - NCT05141253RecruitingEarly Phase 1
Trial of RD133 for mesothelin-positive tumors after prior treatment
This early-stage trial tests whether RD133 can be safe and effective for people whose solid tumors have a high “mesothelin” marker and that have not responded to at least two standard treatments. If you qualify, you’ll be checked closely for side effects and whether the tumor responds.
Wuhan, HubeiAges 18 years+ - NCT05338931RecruitingPhase 1/Phase 2
AT101 for relapsed or refractory B-cell lymphoma patients
This trial studies AT101 to see how safe it is, what side effects it causes, and whether it can help people with B-cell non-Hodgkin lymphoma that has come back or did not respond to treatment. It may be an option if your usual treatments are no longer working or aren’t suitable for you.
SeoulAges 19 years+ - NCT05521204RecruitingPhase 2
Olverembatinib for cancers with FGFR1 gene changes
This trial studies olverembatinib to treat certain blood cancers that have an FGFR1 rearrangement (a specific gene change). It’s for people whose disease is newly diagnosed, has progressed, or has come back, and who can safely take the study medicine and attend follow-up visits.
Suzhou, JiangsuAges Any age - NCT05552937RecruitingPhase 2
Tafasitamab plus lenalidomide for relapsed large B-cell lymphoma
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
Hangzhou, ZhejiangAges 18 years+ - NCT05521802RecruitingPhase 1/Phase 2
Testing a new CAR-T therapy for relapsed myeloma
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
TianjinAges 18 years+ - NCT05539833RecruitingEarly Phase 1
TCR-T cell therapy for HLA-A2 positive solid tumors
This early-phase study tests a personalized immune-cell treatment (TCR-T cells) made from your own immune cells. You may qualify if you have a solid tumor that shows a specific target on tumor cells and your body type (HLA-A2) matches what the therapy needs.
Nanning, GuangxiAges 18–70 - NCT04920617RecruitingPhase 2
Vaccine plus pembrolizumab, with or without low-dose chemo
This Phase 2 study tests whether a cancer vaccine called DPX-Survivac, along with pembrolizumab (an immune medicine), can help shrink diffuse large B-cell lymphoma (DLBCL) that has come back or not responded. It also looks at whether adding intermittent low-dose cyclophosphamide (a low-dose chemotherapy) improves results.
Fountain Valley, CaliforniaAges 18 years+ - NCT05811975RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors
This early-phase study tests a personalized treatment made from your own immune cells to attack solid tumors that have not responded to standard care. If you qualify, the team will collect blood cells, prepare the therapy, and give it back to you with close monitoring for safety and early signs of benefit.
Nanning, GuangxiAges 18–70 - NCT05842707RecruitingPhase 1/Phase 2
Cord blood CAR cells for hard-to-treat B-cell lymphoma
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05846763Recruiting
Obinutuzumab plus lenalidomide for returning follicular lymphoma
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
TianjinAges 18 years+ - NCT05931328RecruitingPhase 2
Thiotepa plus pomalidomide for recurrent brain lymphoma
This Phase 2 trial tests a combination medicine (thiotepa plus pomalidomide) for people whose primary central nervous system lymphoma has come back or did not respond to prior chemotherapy. It may help shrink lymphoma in the brain/spinal fluid and improve disease control.
Nanjing, JiangsuAges 18–75 - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory acute myeloid leukemia (aml)?
- Yes. Clin2 currently lists 1,349 recruiting relapsed or refractory acute myeloid leukemia (aml) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory acute myeloid leukemia (aml) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory acute myeloid leukemia (aml) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Leukemia Acute Myeloid - AML
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.